Literature DB >> 19447360

Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.

Lori A Daiello1, Brian R Ott, Kate L Lapane, Steven E Reinert, Jason T Machan, David D Dore.   

Abstract

BACKGROUND: Cholinesterase inhibitors (CHEIs) ameliorate some types of behavioral symptoms in patients with Alzheimer's disease. However, there has been little previous study of the outcomes associated with discontinuing these medications.
OBJECTIVE: The primary aim of this study was to evaluate the extent to which discontinuing CHEI therapy affected behavioral and mood symptoms in a cohort of nursing home residents with a diagnosis of dementia compared with residents receiving longer-term CHEI therapy.
METHODS: This was a retrospective cohort study using Rhode Island Medicaid prescription claims and the Minimum Data Set (MDS). Participants were Rhode Island nursing home residents aged > or =60 years with a diagnosis of Alzheimer's disease or non-Alzheimer's dementia, treated with CHEI monotherapy, and enrolled in the Medicaid program between January 1, 2004, and December 31, 2005. The discontinuation cohort (CHEI-DC) was selected by identifying residents who received 3 to 9 months of uninterrupted CHEI therapy. The continuation cohort (CHEI-CONT) was prescribed continuous CHEI therapy for >9 months. Changes in scores on the Aggressive Behavior Scale (ABS) and the Depression Rating Scale (DRS) for CHEI-DC residents were compared with changes in scores for CHEI-CONT residents. Secondary outcomes included change over time for individual behavioral symptoms and indicators of cognitive and functional status coded on the MDS.
RESULTS: The final matched sample (N = 178) included 62 CHEI-DC cases and 116 CHEI-CONT controls. More than half of the cohort was aged > or =85 years, and the sample was predominantly female. A diagnosis of Alzheimer's disease was documented in 40.3% of the CHEI-DC patients and in 46.5% of the CHEI-CONT patients. Behavioral worsening, indicated by an increase in the estimated mean monthly point change in ABS score, occurred in the CHEI-DC group (0.08; 95% CI, 0.01 to 0.16) but not in the CHEI-CONT group (-0.01; 95% CI, -0.06 to 0.04), and the between-group difference was significant (0.09; 95% CI, 0.01 to 0.18). There were no significant between-group differences in the mean monthly point change in mood symptoms on the DRS (0.04; 95% CI, -0.03 to 0.12). For the secondary outcomes, the mean monthly MDS point change for frequency of repetitive verbal behaviors indicated that CHEI-DC patients exhibited significantly more episodes of repetitive questioning (0.17; 95% CI, 0.05 to 0.29) and repetitive health complaints (0.16; 95% CI, 0.04 to 0.27) compared with CHEI-CONT residents. Continued use of CHEIs was associated with more time spent in leisure-related activities over the study period (-0.26; 95% CI, -0.50 to -0.02), with the CHEI-DC group spending less time in activities (0.11; 95% CI, 0 to 0.23); the between-group difference was also significant (0.37; 95% CI, 0.10 to 0.65).
CONCLUSION: Results of this retrospective analysis suggest that, compared with longer duration of CHEI therapy, discontinuation of CHEIs in these nursing home residents with dementia was associated with some adverse behavioral changes and decreased time spent engaging in leisure-related activities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447360     DOI: 10.1016/j.amjopharm.2009.04.002

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  15 in total

Review 1.  Drug therapy optimization at the end of life.

Authors:  Alfonso J Cruz-Jentoft; Benoit Boland; Lourdes Rexach
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

Review 2.  Withdrawal of Antidementia Drugs in Older People: Who, When and How?

Authors:  Carole Parsons
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

Review 3.  Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.

Authors:  David B Hogan
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

Review 4.  The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.

Authors:  William James Deardorff; Eliahu Feen; George T Grossberg
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

Review 5.  Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying?

Authors:  Carole Parsons; Carmel M Hughes; A Peter Passmore; Kate L Lapane
Journal:  Drugs Aging       Date:  2010-06-01       Impact factor: 3.923

6.  A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study.

Authors:  Virginie Gardette; Maryse Lapeyre-Mestre; Antoine Piau; Adeline Gallini; Christelle Cantet; Jean-Louis Montastruc; Bruno Vellas; Sandrine Andrieu
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

7.  Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia.

Authors:  Carole Parsons; Becky A Briesacher; Jane L Givens; Yong Chen; Jennifer Tjia
Journal:  J Am Geriatr Soc       Date:  2011-06-13       Impact factor: 5.562

8.  Impact of deprescribing AChEIs on aggressive behaviors and antipsychotic prescribing.

Authors:  Joshua D Niznik; Xinhua Zhao; Meiqi He; Sherrie L Aspinall; Joseph T Hanlon; David Nace; Joshua M Thorpe; Carolyn T Thorpe
Journal:  Alzheimers Dement       Date:  2020-02-13       Impact factor: 21.566

Review 9.  Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors.

Authors:  Colleen J Maxwell; Kathryn Stock; Dallas Seitz; Nathan Herrmann
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

10.  Drug Prescriptions in Nursing Home Residents during their Last 6 Months of Life: Data from the IQUARE Study.

Authors:  S Sourdet; C Rochette; P de Souto Barreto; F Nourhashemi; A Piau; B Vellas; Y Rolland
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.